How to buy Catalyst Pharmaceuticals stock | $3.72

Catalyst Pharmaceuticals, Inc is a biotechnology business based in the US. Catalyst Pharmaceuticals shares (CPRX) are listed on the NASDAQ and all prices are listed in US Dollars. Catalyst Pharmaceuticals employs 74 staff and has a trailing 12-month revenue of around 0.00.

Catalyst Pharmaceuticals share price

Use our graph to track the performance of CPRX stocks over time.

Catalyst Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-04-30.

Latest market close	$3.72
52-week range	$2.88 - $5.19
50-day moving average	$4.40
200-day moving average	$3.80
Wall St. target price	$7.50
PE ratio	6.6901
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.71

Buy Catalyst Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Catalyst Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Catalyst Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Catalyst Pharmaceuticals price performance over time

Historical closes compared with the close of $3.72 from 2021-03-10

1 week (2021-04-29)	-21.68%
1 month (2021-04-07)	-14.87%
3 months (2021-02-05)	-14.87%
6 months (2020-11-06)	18.10%

1 year (2020-05-06)	-21.35%
2 years (2019-05-06)	-39.12%
3 years (2018-05-04)	37.27%
5 years (2016-05-06)	511.34%

Is Catalyst Pharmaceuticals under- or over-valued?

Valuing Catalyst Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Catalyst Pharmaceuticals's P/E ratio

Catalyst Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, Catalyst Pharmaceuticals shares trade at around 7x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Catalyst Pharmaceuticals's EBITDA

Catalyst Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $41.4 million.

The EBITDA is a measure of a Catalyst Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Catalyst Pharmaceuticals financials

Revenue TTM	$119.1 million
Operating margin TTM	34.69%
Gross profit TTM	$87.1 million
Return on assets TTM	16.94%
Return on equity TTM	58.3%
Profit margin	62.97%
Book value	$1.63
Market capitalisation	$493.2 million

TTM: trailing 12 months

Shorting Catalyst Pharmaceuticals shares

There are currently 11.7 million Catalyst Pharmaceuticals shares held short by investors – that's known as Catalyst Pharmaceuticals's "short interest". This figure is 5.3% down from 12.4 million last month.

There are a few different ways that this level of interest in shorting Catalyst Pharmaceuticals shares can be evaluated.

Catalyst Pharmaceuticals's "short interest ratio" (SIR)

Catalyst Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Catalyst Pharmaceuticals shares currently shorted divided by the average quantity of Catalyst Pharmaceuticals shares traded daily (recently around 1.7 million). Catalyst Pharmaceuticals's SIR currently stands at 6.75. In other words for every 100,000 Catalyst Pharmaceuticals shares traded daily on the market, roughly 6750 shares are currently held short.

However Catalyst Pharmaceuticals's short interest can also be evaluated against the total number of Catalyst Pharmaceuticals shares, or, against the total number of tradable Catalyst Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Catalyst Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Catalyst Pharmaceuticals shares in existence, roughly 110 shares are currently held short) or 0.1213% of the tradable shares (for every 100,000 tradable Catalyst Pharmaceuticals shares, roughly 121 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Catalyst Pharmaceuticals.

Find out more about how you can short Catalyst Pharmaceuticals stock.

Catalyst Pharmaceuticals share dividends

We're not expecting Catalyst Pharmaceuticals to pay a dividend over the next 12 months.

Catalyst Pharmaceuticals share price volatility

Over the last 12 months, Catalyst Pharmaceuticals's shares have ranged in value from as little as $2.875 up to $5.19. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Pharmaceuticals's is 1.3762. This would suggest that Catalyst Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Catalyst Pharmaceuticals overview

Catalyst Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc. ; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc.

Frequently asked questions

• What percentage of Catalyst Pharmaceuticals is owned by insiders or institutions?

  Currently 6.971% of Catalyst Pharmaceuticals shares are held by insiders and 66.13% by institutions.

• How many people work for Catalyst Pharmaceuticals?

  Latest data suggests 74 work at Catalyst Pharmaceuticals.

• When does the fiscal year end for Catalyst Pharmaceuticals?

  Catalyst Pharmaceuticals's fiscal year ends in December.

• Where is Catalyst Pharmaceuticals based?

  Catalyst Pharmaceuticals's address is: 355 Alhambra Circle, Coral Gables, FL, United States, 33134

• What is Catalyst Pharmaceuticals's ISIN number?

  Catalyst Pharmaceuticals's international securities identification number is: US14888U1016

• What is Catalyst Pharmaceuticals's CUSIP number?

  Catalyst Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 14888U101